Delcath Systems Announces Second Quarter 2021 Results
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021.
Recent Business Highlights
During and since the second quarter the company:
- Had positive efficacy results presented from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma (mOM) at the American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation by the study’s Lead Investigator, Dr. Jonathan Zager, Chief Academic Officer, Chair, USF Department of Oncologic Sciences, Moffitt Cancer Center, included data based on 79 of 91 treated HEPZATO patients showing an overall response rate of
29.2% with a95% confidence interval lower bound of20% . Given the magnitude by which the lower bound exceeded the8.3% prespecified threshold for success, the primary endpoint of the trial has been met regardless of the outcome of patients who have not yet been evaluated. Patient level response data were also presented for this same patient set, indicating that44% of evaluable patients in the HEPZATO arm had a30% or greater reduction in target tumor lesions at one or more time points versus17% for patients enrolled in the Best Alternative Care arm. - Announced that the United Kingdom’s National Institute for Health and Care Excellence, has updated its guidance for the Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) in the treatment of patients with metastases in the liver from Ocular Melanoma. Under this designation, private insurance may be more likely to fund treatment with CHEMOSAT, some regional funding may be more accessible, and a process is now available to seek national reimbursement.
- Entered into a debt facility with Avenue Venture Opportunities Fund, L.P. providing up to
$20 million with an initial$15 million funded at close - Was added to the Russell Microcap® Index. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“During the quarter we announced new patient level data at ASCO that further strengthens the case that HEPZATO would offer a compelling clinical benefit to patients were it approved by the FDA,” said Gerard Michel, CEO of Delcath. “With additional capital from the just closed transaction with Avenue Venture Opportunities Fund, Delcath has the required resources to accomplish its strategic priorities – the filing of the HEPZATO NDA in early 2022, preparing for the subsequent US launch when approved, and expanding the development of HEPZATO into additional areas of high unmet need.”
First Quarter 2021 Financial Results:
Income Statement Highlights.
Product revenue for the three months ended June 30, 2021 was approximately
The company recorded a net loss for the three months ended June 30, 2021, of
Balance Sheet Highlights.
On June 30, 2021, we had cash, cash equivalents and restricted cash totaling
On August 6th, we closed a
Also, on August 6th, we amended two existing convertible notes through an extension of the term of the notes until 2024 and lowered the conversion factor in consideration for the notes becoming subordinate to the Avenue Venture Fund debt.
Additional details concerning the Avenue Venture Fund facility and modification of the existing convertible notes will be contained in the company's Current Report on Form 8-K to be filed with the Securities and Exchange Commission.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: August 10, 2021
Time: 8:30 AM Eastern Time
Toll Free: 877-545-0523; Entry Code: 148562
International: 973-528-0016; Entry Code: 148562
The call will also be available over the Internet and accessible at:
https://www.webcaster4.com/Webcast/Page/2475/42376
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Safe Harbor / Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials, including without limitation the mOM and ICC clinical trial programs, as well as the receipt of additional data and the performance of additional analyses with respect to the mOM clinical trial, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the impact of the COVID-19 pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company’s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
DELCATH SYSTEMS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share data)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 19,274 | $ | 28,575 | ||||
| Restricted cash | 151 | 181 | ||||||
| Accounts receivable, net | 75 | 57 | ||||||
| Inventories | 1,221 | 855 | ||||||
| Prepaid expenses and other current assets | 2,185 | 2,670 | ||||||
| Total current assets | 22,906 | 32,338 | ||||||
| Property, plant and equipment, net | 1,361 | 1,351 | ||||||
| Right-of-use assets | 650 | 946 | ||||||
| Total assets | $ | 24,917 | $ | 34,635 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,224 | $ | 1,774 | ||||
| Accrued expenses | 3,621 | 5,241 | ||||||
| Deferred revenue, current | 509 | 525 | ||||||
| Lease liabilities, current | 387 | 495 | ||||||
| Convertible notes payable, current | — | 2,000 | ||||||
| Total current liabilities | 5,741 | 10,035 | ||||||
| Deferred revenue, non-current | 1,754 | 2,072 | ||||||
| Lease liabilities, non-current | 263 | 450 | ||||||
| Convertible notes payable, non-current | 2,000 | — | ||||||
| Total liabilities | 9,758 | 12,557 | ||||||
| Commitments and contingencies (Note 11) | — | — | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, $.01 par value; 10,000,000 shares authorized; 11,707 and 20,631 shares issued and outstanding at June 30, 2021, and December 31, 2020, respectively | — | — | ||||||
| Common stock, $.01 par value; 40,000,000 shares authorized; 7,349,777 and 5,996,101 shares issued and outstanding at June 30, 2021, and December 31, 2020, respectively | 74 | 60 | ||||||
| Additional paid-in capital | 423,660 | 417,449 | ||||||
| Accumulated deficit | (408,504 | ) | (395,327 | ) | ||||
| Accumulated other comprehensive loss | (71 | ) | (104 | ) | ||||
| Total stockholders' equity | 15,159 | 22,078 | ||||||
| Total liabilities and stockholders' equity | $ | 24,917 | $ | 34,635 | ||||
DELCATH SYSTEMS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| (in thousands, except share and per share data) | |||||||||||||||
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Product revenue | $ | 398 | $ | 262 | $ | 659 | $ | 437 | |||||||
| Other revenue | 138 | 117 | 265 | 235 | |||||||||||
| Cost of goods sold | (202 | ) | (168 | ) | (314 | ) | (246 | ) | |||||||
| Gross profit | 334 | 211 | 610 | 426 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development expenses | 3,497 | 2,223 | 7,204 | 5,197 | |||||||||||
| Selling, general and administrative expenses | 3,288 | 2,257 | 6,584 | 4,573 | |||||||||||
| Total operating expenses | 6,785 | 4,480 | 13,788 | 9,770 | |||||||||||
| Operating loss | (6,451 | ) | (4,269 | ) | (13,178 | ) | (9,344 | ) | |||||||
| Change in fair value of the warrant liability, net | — | — | — | (2,832 | ) | ||||||||||
| Interest expense, net | (40 | ) | (52 | ) | (81 | ) | (88 | ) | |||||||
| Other income | 61 | 46 | 82 | 128 | |||||||||||
| Net loss | (6,430 | ) | (4,275 | ) | (13,177 | ) | (12,136 | ) | |||||||
| Deemed dividend for triggering of warrant down round feature | — | (55 | ) | — | (55 | ) | |||||||||
| Net loss attributable to common stockholders | $ | (6,430 | ) | $ | (4,330 | ) | $ | (13,177 | ) | $ | (12,191 | ) | |||
| Net loss | $ | (6,430 | ) | $ | (4,275 | ) | $ | (13,177 | ) | $ | (12,136 | ) | |||
| Other comprehensive (loss) income: | |||||||||||||||
| Foreign currency translation adjustments | (61 | ) | (1 | ) | 33 | 65 | |||||||||
| Total other comprehensive loss | $ | (6,491 | ) | $ | (4,276 | ) | $ | (13,144 | ) | $ | (12,071 | ) | |||
| Common share data: | |||||||||||||||
| Basic loss per common share | $ | (0.96 | ) | $ | (1.90 | ) | $ | (2.00 | ) | $ | (10.40 | ) | |||
| Diluted loss per common share | $ | (0.96 | ) | $ | (1.90 | ) | $ | (2.00 | ) | $ | (10.40 | ) | |||
| Weighted average number of basic shares outstanding | 6,681,369 | 2,273,187 | 6,589,655 | 1,171,994 | |||||||||||
| Weighted average number of diluted shares outstanding | 6,681,369 | 2,273,187 | 6,589,655 | 1,171,994 | |||||||||||
